Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection
Minutolo A, Petrone V, Fanelli M, Maracchioni C, Giudice M, Teti E, Coppola L, Sorace C, +11 more
International Immunopharmacology (2023) · n=30
An ex-vivo study from the Garaci–Matteucci group examining lymphocyte populations in 10 PASC patients, 15 acute-COVID-19 controls, and 5 healthy donors — the only PASC-specific thymosin α-1 paper in the indexed literature, documenting persistent immune dysregulation and partial ex-vivo rescue with greatest effect in patients who had required respiratory support during the acute phase.
This 2023 International Immunopharmacology paper from the Minutolo, Garaci and Matteucci group at Tor Vergata in Rome is the only post-acute SARS-CoV-2 sequelae (PASC) -specific thymosin α-1 publication in the indexed literature and the cornerstone direct-evidence reference for the thymosin α-1 section of the long-COVID-and-peptides dossier. The investigators characterised peripheral blood mononuclear cell phenotypes in three groups: 10 PASC patients (sampled approximately 7–8 months after the acute phase), 15 acute-COVID-19 controls, and 5 healthy donors. The study design combined immune-phenotyping flow cytometry (T-cell differentiation and exhaustion markers, B-cell subpopulations, intracellular cytokines) with real-time PCR quantification of inflammatory cytokine messenger RNA, paired with an ex-vivo intervention arm in which diluted blood samples were exposed to 50 μg/mL thymosin α-1 for 48 hours at 37°C in 5% CO₂ before reanalysis.
The baseline PASC immune phenotype reported is consistent with chronic immune stimulation: persistent depletion of naive B-cell and T-cell subpopulations, expansion of memory T cells, and elevated frequency of PD-1-positive (exhausted-phenotype) T cells against healthy donor controls. The ex-vivo thymosin α-1 exposure was reported to shift several of these markers towards homeostatic profiles. In the CD4+ compartment, central memory cells decreased with a shift towards effector memory, PD-1 expression was significantly reduced, and IL-10-expressing cells increased. In the CD8+ compartment, PD-1-positive and terminally differentiated cells were significantly reduced, naive cells increased (a finding pronounced in the subgroup with respiratory-support history), and terminal effector memory cells decreased. Intracellular cytokine staining showed a significant decrease in cells expressing IL-6 and IFN-γ in both CD4+ and CD8+ T-cell compartments and a significant increase in IL-10-expressing cells, with the IL-6 reduction most pronounced in activated CD38+ CD8+ cells. Subgroup analyses indicated that the ex-vivo rescue was strongest in patients with a severe acute-illness history, in those who had required respiratory support during the acute phase, and in those with persistent systemic and psychiatric symptoms.
This is an ex-vivo characterisation study, not an interventional randomised trial. The intervention is administration of thymosin α-1 to blood already drawn from PASC patients in a culture-medium context for 48 hours; the inference that ex-vivo restoration of lymphocyte-subset profiles predicts clinically meaningful in-vivo benefit on PASC symptoms is mechanism extrapolation, not outcome data. The sample size — 10 PASC patients, 15 acute-COVID controls, 5 healthy donors — would be considered exploratory in any other clinical-trial context and limits the strength of the subgroup observations particularly; the respiratory-support and severity-grade subgroup findings are based on subsets within a 10-patient PASC cohort. The 50 μg/mL ex-vivo dose is a culture-system concentration chosen to characterise responsiveness, not a translation of in-vivo systemic exposure; clinical thymosin α-1 dosing (the approved hepatitis B and C indications use 1.6 mg subcutaneous twice weekly) produces substantially different and time-varying tissue concentrations. The 7–8 month time-from-acute-infection sampling profile is one slice through a PASC condition where symptom-pathophysiology relationships are known to shift across longer post-acute windows; the findings should not be generalised beyond comparable post-acute time points. The Garaci group has long-standing scientific and clinical involvement with thymosin α-1; that history is mechanistically informative but is a structural prior that readers should be aware of when reading the paper's framing. No published interventional thymosin α-1 trial in PASC has read out as of 2026; the NCT04487444 family of programmes is the closest parallel and remains incomplete in published form for the post-acute indication.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.